山东华特达因健康股份有限公司 第十一届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东华特达因健康股份有限公司第十一届监事会于 2025 年 4 月 7 日以电子邮件形式发出召开第三次会议的通知，并于 2025 年 4 月 17 日在公司会议室召开会议。会议应参加监事 5 名，实际参加监事 5 名。会议由监事会主席沈宝杰先生主持。会议符合有关法律、法规、 规章和《公司章程》的规定。 股票代码：000915 股票简称：华特达因 公告编号：2025-018 经审核，监事会认为董事会编制和审议《公司 2025 年第一季度 报告》的程序符合法律法规及深圳证券交易所规定的要求，报告内容 真实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记 载、误导性陈述或者重大遗漏。 （三）备查文件 经与会监事签字并加盖监事会印章的监事会决议。 特此公告 山东华特达因健康股份有限公司监事会 二、监事会会议审议情况 以 5 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2025 年第一季度报告》并发表如下审核意见 ...

山东华特达因健康股份有限公司 证券代码：000915 证券简称：华特达因 公告编号：2025-015 第十一届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 于召开公司 2024 年年度股东会的议案》，决定于 2025 年 5 月 13 日召 开公司 2024 年年度股东会。 三、备查文件 经与会董事签字并加盖董事会印章的董事会决议。 特此公告 1.以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2025 年第一季度报告》。 2.以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了《关 于聘请 2025 年度会计师事务所的议案》，提交公司 2024 年年度股东 会审议。 聘请致同会计师事务所（特殊普通合伙）为公司 2025 年度的财 务审计及内部控制审计机构，费用 45 万元，其中财务审计 37 万元， 内部控制审计 8 万元。 本议案提交董事会前，已经第十一届董事会审计委员会第三次会 议审议通过。 3.以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了《关 山东华特达因健 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 616,291,375.97, representing a 7.78% increase compared to CNY 571,800,385.84 in the same period last year[4] - Net profit attributable to shareholders for Q1 2025 was CNY 182,345,987.39, an increase of 8.13% from CNY 168,635,228.17 year-over-year[4] - The net profit after deducting non-recurring gains and losses was CNY 179,265,608.33, reflecting a 10.79% increase compared to CNY 161,806,595.60 in the previous year[4] - Total operating revenue for Q1 2025 reached ¥616,291,375.97, an increase of 7.9% compared to ¥571,800,385.84 in Q1 2024[15] - Operating profit for the period was ¥406,682,555.92, up from ¥375,477,072.98, reflecting a growth of 8.3%[15] - Net profit attributable to the parent company was ¥182,345,987.39, compared to ¥168,635,228.17 in the previous year, marking an increase of 8.5%[16] - The basic earnings per share for the period was ¥0.78, up from ¥0.72, representing an increase of 8.3%[16] Cash Flow and Investments - The net cash flow from operating activities decreased significantly by 76.42%, amounting to CNY 54,158,675.30, down from CNY 229,718,341.80 in the same quarter last year[4] - Cash inflow from operating activities was ¥583,519,973.25, down from ¥665,941,990.00, a decrease of 12.4%[17] - The net cash flow from operating activities was $54,158,675.30, a decrease of 76.4% compared to $229,718,341.80 in the previous period[18] - Cash outflow from investing activities totaled $900,040,021.22, an increase of 22.1% from $736,924,140.36 in the prior period[18] - The net cash flow from investing activities was -$146,958,058.49, contrasting with a positive cash flow of $6,710,675.52 previously[18] - The cash inflow from investment activities was $753,081,962.73, slightly up from $743,634,815.88 in the previous period[18] - The company reported a net increase in cash and cash equivalents of -$92,799,383.19, compared to an increase of $2,790,962.32 in the prior period[18] Assets and Liabilities - Total assets at the end of Q1 2025 reached CNY 5,156,848,902.20, a 4.58% increase from CNY 4,930,936,591.73 at the end of the previous year[4] - Total assets increased to ¥5,156,848,902.20 from ¥4,930,936,591.73, representing a growth of 4.6%[14] - Total liabilities rose to ¥902,978,082.34, up from ¥518,499,753.28, indicating a significant increase of 74.0%[14] - The company's total current assets as of March 31, 2025, amount to CNY 3,746,489,988.74, an increase from CNY 3,510,737,250.04 at the beginning of the period[12] - The total non-current assets are valued at CNY 1,470,000,000.00, with fixed assets at CNY 840,028,196.41[12] Shareholder Equity and Structure - Shareholders' equity attributable to the parent company increased by 6.26% to CNY 3,093,997,428.26 from CNY 2,911,651,440.88 at the end of the last year[4] - The company's total equity attributable to shareholders reached ¥3,093,997,428.26, compared to ¥2,911,651,440.88, an increase of 6.3%[14] - The largest shareholder, Shandong Huate Holding Group Co., Ltd., holds 22.00% of the shares, totaling 51,544,340 shares[10] - There are no significant changes in the shareholder structure or related party transactions reported[10] Other Financial Metrics - The weighted average return on equity rose to 6.07%, an increase of 0.57 percentage points from 5.50% in the previous year[4] - The company reported a significant increase in accounts receivable by 55.02%, totaling CNY 384,123,102.63 due to an increase in bank acceptance bills held[7] - Prepayments increased by 115.04% to CNY 73,973,722.89, attributed to higher advance payments to suppliers[7] - Other payables surged by 605.54% to CNY 522,918,269.00, primarily due to increased dividends payable from the subsidiary Dain Pharmaceutical[7] - Research and development expenses increased to ¥14,462,161.65 from ¥12,559,406.43, reflecting a growth of 15.2%[15] Audit and Reporting - The first quarter report was not audited, indicating a potential area for further scrutiny in financial reporting[19]

Core Insights - The company reported a revenue of 616 million yuan for the first quarter of 2025, representing a year-on-year growth of 7.78% [1] - The net profit for the same period was 182 million yuan, showing an increase of 8.13% compared to the previous year [1]

证券代码：000915 证券简称：华特达因 公告编号：2025-017 山东华特达因健康股份有限公司 关于拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 本次拟续聘会计师事务所符合财政部、国务院国资委、证监会印发的 《国有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号） 的规定。 （三）诚信记录 致同所近三年因执业行为受到刑事处罚 0 次、行政处罚 2 次、监督管理 措施 15 次、自律监管措施 9 次和纪律处分 0 次。58 名从业人员近三年因 执业行为受到刑事处罚 0 次、行政处罚 11 次、监督管理措施 16 次、自律 监管措施 8 次和纪律处分 1 次。 二、项目信息 （一）人员信息 刘健，2007 年成为注册会计师，1998 年开始从事上市公司审计，2019 年开始在本所执业；近三年签署上市公司审计报告 8 份、签署新三板挂牌 公司审计报告 1 份。复核新三板挂牌公司 1 份。 山东华特达因健康股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开第十一届董事会第三次会议，审议通 ...

Group 1: Report Overview - Reported industry: Chemical Pharmaceuticals [2] - Research object: Watertime [17] - Reception time: April 16, 2025 [17] - Listed company reception staff: President Yang Jie, Independent Director Du Ning, Financial Controller Tan Lifu, Board Secretary Fan Liming [17] Group 2: Core Views - The company's cooperation with China Resources Sanjiu on Vitamin D Drops (capsule type) allows for complementary advantages and resource sharing, promoting the popularization of vitamin D supplements [24][44] - In 2024 Q3, the company's performance decline was due to factors such as the slowdown in the pharmaceutical industry, inactive market terminal sales, and intensified pharmacy competition. The company responded by increasing marketing efforts and optimizing strategies [25][45] - The company is promoting the bankruptcy of Watertime Information, the dissolution and liquidation of Watertime Zhixin, and addressing the asset occupation issue of Yinan Watertime Wolong School [26] - The company aims to form multi - category flagship products, optimize channel layout, and build an honest, capable, efficient, and pragmatic corporate culture [26] - The company will adhere to its core marketing strategy, accelerate the layout of OTC and new retail channels, and expand sales through multiple measures to ensure stable performance growth [28][40] Group 3: Q&A Summaries Business and Strategy - The company's mission is to make thousands of Chinese children healthy and strong and become a leading enterprise in the field of children's health care and treatment. It focuses on the pharmaceutical main business, implements category extension and brand extension strategies, and expands the applicable age of Yikexin [34][41] - The company will actively manage its market value through measures such as standardized and transparent information disclosure, strengthening communication with investors, and implementing high - proportion dividends [34][35][42] - In 2025, the company will continue to improve the key technology platform for children's drugs, aiming for breakthroughs in children's respiratory and mental medications [35] Product - related - Yikexin has a market share of over 60%. The company will promote the "AD co - supplementation, 0 - 18 years old, one capsule per day" concept through various channels [34][37] - The company's product line is rich. In addition to Yikexin, products like Dain Tie, Dain Gai, and Xiao'er Ibuprofen Suppository have a broad market space and stable revenue growth [29] - The company's DHA products are designed for 0 - 12 - year - old children to promote eye and brain development, with different formulations to cover a wide range of customers [40] Market and Competition - The company will adhere to its core marketing strategy, strengthen brand promotion, and accelerate the layout of OTC and new retail channels to deal with the impact of competitors' centralized procurement [29][49] - The company's products are mainly sold through dealers, and it has established teams for hospitals, business, OTC, and new retail. The 2024 R & D investment was 97.1389 million yuan, accounting for 4.55% of revenue [47][48] Finance and Dividends - The company will maintain high - proportion dividends in the absence of major business investments and capital requirements, sharing development benefits with shareholders [38][39][47] Industry Outlook - The Chinese pharmaceutical industry is in a period of dual benefits from innovation and policy support, showing an expanding scale and rapid structural optimization. The children's pharmaceutical industry is moving towards precision and safety improvement [36]

Group 1: Company Performance and Financials - The company has maintained a high dividend payout, with the dividend amount for 2024 reaching 119% of the net profit attributable to the parent company [12] - In 2024, the company reported a significant decline in performance, with revenue and profit showing negative growth for the first time since 2019 [10][12] - R&D investment for 2024 was approximately 97.14 million, accounting for 4.55% of revenue [12] Group 2: Market Strategy and Product Development - The company focuses on children's health products, with a mission to become a leader in pediatric healthcare [10] - The market strategy emphasizes "expert authority recommendation, convenient purchasing channels, and professional category education" [11][12] - The company plans to expand the age range for its flagship product, Yikexin, from 0-6 years to 0-18 years, in line with new clinical guidelines [5][10] Group 3: Challenges and Responses - The decline in performance is attributed to a slowdown in the pharmaceutical industry, reduced market activity, and intensified competition among pharmacies [11][12] - The company is actively responding to market changes by increasing marketing efforts and enhancing online channel development [11][12] - The company aims to maintain stable growth by optimizing product structure and increasing R&D investment to introduce more competitive products [12] Group 4: Collaboration and Partnerships - The company collaborates with China Resources Sanjiu as the exclusive agent for its vitamin D products, enhancing market promotion and distribution [11] - Strategic partnerships with major distributors and e-commerce platforms are being strengthened to boost sales and market presence [12] Group 5: Future Outlook - The company is optimistic about the future of the pediatric pharmaceutical market, driven by increasing healthcare demands and supportive government policies [5][10] - Plans for 2025 include focusing on innovation in pediatric medications and expanding the product line to include more health supplements [10][12]

关于举行 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：000915 证券简称：华特达因 公告编号：2025-014 山东华特达因健康股份有限公司 欢迎广大投资者积极参与本次业绩说明会。 特此公告 山东华特达因健康股份有限公司董事会 2025年4月9日 山东华特达因健康股份有限公司（以下简称"公司"）定于 2025 年 4 月 16 日（周三）15:00-16:00 在全景网举办 2024 年度业绩说明 会，本次业绩说明会将采用网络远程的方式举行，投资者可登录全景 网"投资者关系互动平台"（http://ir.p5w.net）参与本次业绩说明 会。 出席本次业绩说明会的人员有：总经理杨杰女士、独立董事杜宁 女士、财务总监谭立富先生、董事会秘书樊黎明先生。 为充分尊重投资者、提升交流的针对性，现就公司 2024 年度网 上业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和 建议。投资者可于 2025 年 4 月 15 日(周二)15:00 前访问 http://ir.p5w.net/zj/或扫描下方二维码， ...

证券代码：000915 证券简称：华特达因 公告编号：2025-013 山东华特达因健康股份有限公司 第十一届董事会2025年第三次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东华特达因健康股份有限公司第十一届董事会于 2025 年 4 月 3 日以电子邮件形式发出召开 2025 年第三次临时会议的通知，并于 2025 年 4 月 7 日以通讯方式召开会议。会议应参加董事 8 名，实际 参加董事 8 名。会议由公司董事长朱效平先生主持。会议符合有关法 律、法规、规章和《公司章程》的规定。 二、董事会会议审议情况 以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了"关于聘 任董事会秘书的议案"： 董事长朱效平提名樊黎明先生（简历见附件）为公司董事会秘书， 任期与第十一届董事会余任任期相同。 董事长朱效平先生不再代行董事会秘书职责。 董事会提名委员会 2025 年第二次会议对拟聘任的董事会秘书进 行了审核，认为：公司本次拟聘任董事会秘书的提名方式符合《公司 法》和《公司章程》的有关规定，拟聘任人员符合上市公 ...

截至公告披露日，李少东先生未持有公司股份。 股票代码：000915 股票简称：华特达因 公告编号：2025-012 山东华特达因健康股份有限公司 关于公司职工代表监事辞职暨补选的公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山东华特达因健康股份有限公司（以下简称"公司"）监事会于 近日收到职工代表监事李少东先生的书面辞职报告。李少东先生因个 人原因辞去第十一届监事会职工代表监事职务。辞职后，李少东先生 仍在公司任职。 根据《公司章程》的规定，李少东先生的辞职报告在公司选举出 新的监事后生效。监事会对李少东先生在任职期间为公司做出的贡献 表示感谢。 2025 年 4 月 1 日，公司 2025 年度临时职工代表大会选举范智胜 先生（简历见附件）为第十一届监事会职工代表监事，任期与第十 一届监事会余任任期相同。 特此公告 山东华特达因健康股份有限公司监事会 截至目前范智胜先生与持有公司股份 5%以上的股东、公司其他 董事、监事、高级管理人员不存在关联关系；未曾受过中国证监会及 其他有关部门的处罚和证券交易所纪律处分；持有公司股份 5000 股； 不存在因涉 ...